COPD - Pharmacological management

Hospital Pharmacist

Volumn 11, Issue 9, 2004, Pages 367-376

  Murphy, Anna C ^a,b,c   Steiner, Michael C ^a  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^b National Respiratory Training Centre   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHYLLINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CARBOCISTEINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; COLCHICINE; CORTICOSTEROID; ERYTHROMYCIN; FORMOTEROL; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; LOSARTAN; MACROLIDE; METHYLXANTHINE DERIVATIVE; MUCOLYTIC AGENT; PHOSPHODIESTERASE IV INHIBITOR; SALBUTAMOL; SALMETEROL XINAFOATE; TACHYKININ RECEPTOR ANTAGONIST; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE; ZILEUTON;

ANXIETY DISORDER; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEVICE; DRUG DELIVERY SYSTEM; GASTROINTESTINAL REFLUX; GLAUCOMA; HEADACHE; HUMAN; HYPOKALEMIA; HYPOXEMIA; NAUSEA; OSTEOPOROSIS; QUALITY OF LIFE; RESTLESSNESS; REVIEW; SIDE EFFECT; SMOKING CESSATION; TACHYCARDIA; TREMOR; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 6344258116     PISSN: 13527967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. National Institute of Clinical Excellence. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59(Suppl 1):1-232
2. Jones PW, Bellamy D, Crockett AWB, Fehrenbach C, Gruffydd-Jones K. Assessing treatment outcomes in COPD. Richmond: Synergy Medical Education; 2001.
3. Teale C, Morrison JF, Page RL, Pearson SB. Dose response to inhaled salbutamol in chronic obstructive airways disease. Postgraduate Medical Journal 1991;67:754-6.
4. Easton PA, Jadue C, Dhingra, S, Anthonisen NR. A comparison of the bronchodilating effects of a beta-2-adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide), given by aerosol alone or in sequence. New England Journal of Medicine 1986;315:735-9.
5. Braun SR, Levy SF. Comparison of ipratropium bromide and albuterol in chronic obstructive pulmonary disease: a three centre study. American Journal of Medicine 1991;91(4A):28S-32S.
6. Appleton S, Smith B, Veale A, Bara A. Long-acting beta-2-agonists for chronic obstructive pulmonary disease. Cochrane Database 2002; issue 2.
7. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, Zu Wallack RL, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. European Respiratory Journal 2002;19:217-24.
8. Disse B, Reichl R, Speck G. BA679BR, a novel long acting bronchodilator. Life Sciences 1993;52:537-44.
9. Minette PA, Barnes PJ. Muscarinic receptor subtypes in lung. Clinical implications. American Review of Respiratory Diseases 1990;141(3, pt 2):S162-S165.
10. Barnes PJ. The pharmacological properties of tiotropium. Chest 2000;117(Suppl 2):S63-6.
11. Van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJ. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000;55:289-94.
12. Vassallo R, Lipsky JJ. Theophylline: recent advances in the understanding of its mode of action and uses in clinical practice. Mayo Clinic Proceedings 1998;73:346-54.
13. Murciano D, Auclair MH, Pariente R, Aubier M. A randomised, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. New England Journal of Medicine 1989;320:1521-5.
14. Aronson JK, Hardman M, Reynolds DJ. ABC of monitoring drug therapy. Theophylline. British Medical Journal 1992;305:1355-8.
15. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-23.
16. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, et al. Long term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive pulmonary disease. New England Journal of Medicine 1999;340:1948-53.
17. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303.
18. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. New England Journal of Medicine 2000;343:1902-9.
19. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998;351:773-80.
20. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-56.
21. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal 2003;21:74-81.
22. Calverley PM, Boonsawat Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal 2003;22;912-9.
23. McEvoy CE, Niewoehner DE. Adverse effects of corticosteroid therapy for COPD. A critical review. Chest 1997;111:732-43.
24. Pelkonen M, Notkola IL, Tukiainen H, Tervahauta M, Tuomilehto J, Nissinen A. Smoking cessation, decline in pulmonary function and total mortality: a 30 year follow up study among the Finnish cohorts of the Seven Countries Study. Thorax 2001;56:703-7.
25. 1. The Lung Health Study. JAMA 1994;272:1497-505.
26. National Institute of Clinical Excellence. National clinical guideline on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation. March 2002.
27. Parrott S, Godfrey C, Raw M, West R, McNeill A. Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Thorax 1998;53 (Suppl 5):S1-S38.
28. Rudolf M, Bellamy D, Burrill P, Scullion J, Thomas M. Consensus guideline for the use of mucolytic therapy in patients with diagnosed COPD. Guidelines 2004;23:119-22.
29. Barnes P. COPD: therapeutic prospects for future management. Future Prescriber 2000:(Oct/Nov);6-9.